Ruggie Capital Group’s Biogen BIIB Stock Holding History

Ruggie Capital Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-140	Closed	-$33K	–	123
2019 Q2	$33K	Buy	+140	New	+$32.3K	0.06%	86
2019 Q1	–	Sell	-12	Closed	-$4K	–	184
2018 Q4	$4K	Buy	+12	New	+$3.83K	﹤0.01%	386
2015 Q3	–	Sell	-27	Closed	-$11K	–	231
2015 Q2	$11K	Hold	27	–	–	0.01%	172
2015 Q1	$11K	Buy	+27	New	+$10.6K	0.01%	134

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Ruggie Capital Group's BIIB Position: Q3 2019 in Review

Ruggie Capital Group sold out of Biogen (BIIB) in Q3 2019, closing a stake of 140 shares — an estimated $33K sold.

Ruggie Capital Group first reported a position in BIIB in Q1 2015 and held it in 4 quarters. The position peaked at $33K in Q2 2019. 989 funds tracked by Wall St. Rank hold BIIB as of Q3 2019.

Ruggie Capital Group reported no remaining Biogen position as of Q3 2019 after selling out during the quarter.
Ruggie Capital Group sold 140 Biogen shares in Q3 2019, an estimated $33K.
Ruggie Capital Group first reported a position in Biogen in Q1 2015 and held it in 4 quarters.
Ruggie Capital Group's Biogen position peaked at $33K in Q2 2019.
989 funds tracked by Wall St. Rank held Biogen as of Q3 2019.

Based on Ruggie Capital Group's 13F filing for Q3 2019, filed 6 Nov 2019.